Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell‐free DNA from non‐small‐cell lung cancer patients with leptomeningeal metastases

Abstract Background Cell‐free tumor DNA (ctDNA) obtained through liquid biopsy is useful for the molecular analysis of advanced non‐small‐cell lung cancer (NSCLC). Few studies have directly compared analysis platforms in terms of their diagnostic performance in analyzing ctDNA obtained from the cerebrospinal fluid (CSF) of patients with leptomeningeal metastasis (LM). Methods We prospectively analyzed patients with epidermal growth factor receptor (EGFR)‐mutant NSCLC who were subjected to CSF analysis for suspected LM. To detect EGFR mutations, CSF ctDNA was analyzed using the cobas EGFR Mutation Test and droplet digital polymerase chain reaction (ddPCR). CSF samples from osimertinib‐refractory patients with LM were also subjected to next‐generation sequencing (NGS). Results Significantly higher rates of valid results (95.1% vs. 78%, respectively, p = 0.04) and EGFR common mutation detection (94.3% vs. 77.1%, respectively, p = 0.047) were obtained through ddPCR than through the cobas EGFR Mutation Test. The sensitivities of ddPCR and cobas were 94.3% and 75.6%, respectively. The concordance rate for EGFR mutation detection through ddPCR and the cobas EGFR Mutation Test was 75.6% and that for EGFR mutation detection in CSF and plasma ctDNA was 28.1%. In osimertinib‐resistant CSF samples, all original EGFR mutations were detected through NGS. MET amplification and CCDC6‐RET fusion were demonstrated in one patient each (9.1%). Conclusions The cobas EGFR Mutation Test, ddPCR, and NGS appear to be feasible methods for analyzing CSF ctDNA in patients with NSCLC and LM. In addition, NGS may provide comprehensive information regarding the mechanisms underlying osimertinib resistance.